Drug Database
OL

olmesartan + azelnidipine (Rezaltas / Rezaltas)

✓ Approved

Daiichi Sankyo Company Limited · AGTR1 · 小分子

什么是 olmesartan + azelnidipine?

olmesartan + azelnidipine 是一种小分子,由Daiichi Sankyo Company Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Rezaltas, Rezaltas
公司Daiichi Sankyo Company Limited
药物类别小分子
分子靶点AGTR1, CACNA1C
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

olmesartan + azelnidipine 作用于 2 个分子靶点:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

olmesartan + azelnidipine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedCell biochemistry and biophysics2026-11-12

Lutein Targets TLR4 as a Potential Immunotherapeutic Strategy for Treatment of Doxorubicin-Induced Cardiomyopathy.

Khedr Eman G EG, Badr Noha H NH, El-Feky Ola A OA

Toll-like receptor 4 is an immune receptor associated with inflammatory diseases, including cardiac conditions. Lutein, a natural carotenoid with potent anti-inflammatory effects, protects against coronary heart disease and other cardiovascular issues. We aimed to explore its potential cardioprotective effects against doxorubicin-induced cardiomyopathy (DIC), focusing on the TLR4/NF-κB and JAK/STAT pathways. We compared its effects with olmesartan, commonly used to manage DIC. This study was performed on five groups of rats: control, doxorubicin (Dox)-treated, lutein-treated, olmesartan-treated, and combination-treated groups. Induction of DIC was performed using Dox (4.5 mg/kg every other day) for ten days. In treatment groups, lutein (50 mg/kg/day) or olmesartan (10 mg/kg/day) was administered for 10 days alongside Dox, while the combination treatment group co-administered lutein (50 mg/kg/day) and olmesartan (10 mg/kg/day) for the same duration alongside Dox. The results indicated that lutein protected cardiomyocytes from Dox-induced histopathological changes, including myocardial fiber disorganization, vascular congestion, and perivascular edema. It decreased the levels of TLR4, NF-κB, p-JAK2, and p-STAT1/3 relative to the Dox group, exhibiting an anti-inflammatory effect through suppression of the TLR4/NF-κB and JAK/STAT pathways. It also had regulatory effects on Akt/mTOR signaling, another pathway linked to TLR4 activation. In comparison to olmesartan, lutein had superior effects on IL-6/JAK2/STAT1/NF-κB and Akt/mTOR levels. Combination treatment also demonstrated cardioprotective effect at histopathological, biochemical, and molecular levels, being more effective than olmesartan on IL-6/NF-κB and Akt/mTOR levels. Moreover, Lutein administration alongside Dox showed anti-inflammatory and cardioprotective effects against DIC, suggesting it as a promising adjunct therapy, either alone or with olmesartan.

PMID 43018900
阅读全文 →
PubMedJournal of pharmaceutical sciences2026-11-11

Spray-dried deep eutectic solvent of Olmesartan medoxomil to modulate solubility, bioavailability, and surface characteristics.

Gangane Purushottam P, Chahande Prashik P, More Sachin S, Warokar Amol A et al.

Olmesartan medoxomil (OLM) is classified as a BCS class II antihypertensive, necessitating an innovative formulation strategy due to its poor aqueous solubility (∼7.75 μg/mL) and low oral bioavailability (∼26%). This study aimed to determine the efficacy of the DESs in improving the biopharmaceutical properties of OLM. Choline chloride (ChCl) was used as the hydrogen bond acceptor (HBA), and urea and glycerol as the hydrogen bond donors (HBDs). An optimized DES system with the appropriate molar ratios of ChCl: urea: glycerol, 1:2:2, exhibited a high solubilization ability of OLM (16.86 ± 0.14 mg/mL). The optimized DES with OLM was then solidified by spray drying with Neusilin® US2, a mesoporous inorganic adsorbent, to yield a free-flowing powder (S-DES 5). FTIR, DSC, PXRD, and SEM characterization confirmed the conversion of crystalline OLM to a molecularly dispersed state in the DES and demonstrated intermolecular hydrogen bonding by spectral shift. In the BET surface area analysis, the mesoporous structure of the SDES-5 showed an average pore diameter of 15.526 nm, pore volume of 0.1265 cm³/g, and a specific surface area of 32.598 m²/g, which indicated good conditions for drug adsorption and stabilization. In vitro dissolution studies showed that the drug release rate of S-DES was much higher, with 96.7% drug released after 60 min, while only 31.8% of the drug was released from pure OLM after 60 min. The oral bioavailability was increased by 2.4 fold in Sprague-Dawley rats, indicated by significantly higher Cmax (448.20 μg/mL) and AUC0-t (5985.435 μg.h/mL). Stability studies were conducted in accelerated conditions, showing a formulation resistance to changes according to the ICH short-term 6-month study. In a nutshell, the findings reported that spray dried DES systems using mesoporous carrier could be a promising and scalable method to modulate the solubility and oral bioavailability of poorly water-soluble drugs.

PMID 43014697
阅读全文 →
PubMedAdvanced pharmaceutical bulletin2026-11-10

Optimization, Ex-Vivo Penetration and In-Vivo Evaluation of Pegylated Nanostructured Lipid Carriers of Olmesartan Medoxomil to Enhance Transdermal Delivery.

Albash Rofida R, Abdelbary Aly A AA, Refai Hanan H, El-Nabarawi Mohamed A MA

Olmesartan medoxomil (OLM), a poorly water soluble hypertension medication with 26% oral bioavailability, was encapsulated in PEGylated nanostructured lipid carriers (PNLCs) for transdermal distribution. Tween 80 or sodium deoxycholate stabilized the PNLCs, which were made up of liquid lipid including a mixture of medium chain triglycerides (labrasol and labrafil) and solid lipid (compritol and tristearin). Hot melt emulsification, high-speed stirring, and ultrasonication were used to create PNLCs. To distinguish the effects of formulation independent variables on entrapment efficiency %, particle size, polydispersity index, zeta potential, and amount of drug released after 6 hours (Q6h), a 24 complete factorial design using Design Expert® software was created. For additional research, the formula (PNLC16) with the best requirements was chosen. When compared to OLM solution, PNLC16 showed higher permeation ex vivo permeation using both shed snake and rat skin. Histopathological analysis demonstrated that the topically administered PNLCs were safe. Pharmacodynamic research further demonstrated PNLC16's superiority over commercial oral pills in terms of long-lasting effects. Accordingly, the results showed that PNLC16 would be a viable vehicle for OLM transdermal delivery.

PMID 43005236
阅读全文 →
PubMedCureus2026-11-09

Celiac Crisis: An Unusual Case of Severe Diarrhea.

Chen Ellie E, Cusumano Vivy V

Celiac disease is an immune-mediated enteropathy triggered by dietary gluten. Celiac crisis is a severe manifestation characterized by profuse diarrhea, dehydration, hypotension, and severe metabolic derangements. We describe the case of an elderly patient with a remote childhood diagnosis of celiac disease who presented in celiac crisis. A 79-year-old man with hypertension managed on olmesartan presented with two weeks of severe watery diarrhea, weight loss, and edema that progressed to hypotension, acute kidney injury, and profound electrolyte abnormalities, necessitating multiple hospitalizations. Celiac serologies were markedly elevated, and he subsequently disclosed a childhood diagnosis of celiac disease that he had believed resolved. Duodenal biopsies demonstrated duodenitis with intraepithelial lymphocytosis and villous blunting. His symptoms persisted despite a gluten-free diet, withholding olmesartan, and supportive care but improved rapidly after initiation of budesonide. He was diagnosed with celiac crisis, with a possible contribution from olmesartan-associated enteropathy. Repeat endoscopy eight months later showed histologic remission. Celiac crisis should be considered in any patient presenting with severe diarrhea, dehydration, and metabolic abnormalities, especially when there is evidence of underlying celiac disease. In this patient, concurrent olmesartan use raised the possibility of a superimposed drug-induced enteropathy; although olmesartan was discontinued five days before budesonide was started, its contribution cannot be excluded and remains a confounding factor. Even so, this case highlights the importance of promptly recognizing celiac crisis and suggests a potential role for budesonide in patients whose symptoms persist despite gluten withdrawal and supportive care.

PMID 43001292
阅读全文 →
PubMedMolecular and cellular biochemistry2026-11-08

Angiotensin II type 1 receptor (AT1R) drives human Tenon's capsule fibroblast activation and myofibroblast transformation via the RhoA/ROCK signaling pathway.

Zhang Yuanyuan Y, Luo Xu X, Zuo Lei L, Cui Hongping H

Although the angiotensin II type 1 receptor (AT1R) participates in systemic tissue remodeling, its exact contribution to human subconjunctival fibrosis remains poorly understood. This study investigated the expression of AT1R in human clinical scar specimens, the downstream involvement of the RhoA/ROCK pathway, and the independent anti-fibrotic effects of receptor blockade. Primary human Tenon's capsule fibroblasts (HTCFs) were isolated from patient tissue biopsies and verified as a pure mesenchymal lineage using immunofluorescence and quantitative real-time PCR (qRT-PCR). To model the scar microenvironment, primary cells were stimulated with transforming growth factor-beta 1 (TGF-β1), either alone or in combination with Angiotensin II, the AT1R antagonist Olmesartan (OMS), or the selective ROCK inhibitor Y-27,632. Profibrotic and structural markers, including AT1R, alpha-smooth muscle actin (α-SMA), RhoA, ROCK1, fibronectin, and collagen I alpha (COL1A1), were quantified via Western blotting, qRT-PCR and immunofluorescence. Cellular proliferation and migration were evaluated using CCK-8 and Transwell migration assays. Our ex vivo tissue analyses revealed that AT1R expression was upregulated at gene and protein levels in human Tenon's capsule scars compared to normal controls. In vitro, stimulation with TGF-β1 induced a dose-dependent upregulation of AT1R alongside core profibrotic biomarkers, while accelerating HTCF proliferation and migration rates. Conversely, treatment with OMS or Y-27,632 counteracted this TGF-β1-induced activation, reversing cellular proliferation, cell motility, and the expression of extracellular matrix components. Together, these findings indicate that subconjunctival fibrosis is driven by AT1R-RhoA/ROCK1 axis which might provide a promising mechanistic pipeline to modulate tissue scarring and optimize outcomes in glaucoma management.

PMID 42998218
阅读全文 →
PubMedBMJ case reports2026-10-27

Olmesartan-associated enteropathy presenting as severe malnutrition.

Mpanda Alinafe A, Sylla Mariame M, Young Eric D ED

PMID 42946496
阅读全文 →

注册免费账户还可查看另外 2035 篇文献

免费注册查看全部文献 →

了解更多olmesartan + azelnidipine